SGMO Sangamo Therapeutics Inc.

9.74
-0.06  -1%
Previous Close 9.8
Open 9.78
Price To Book 2.72
Market Cap 996142458
Shares 102,273,353
Volume 842,070
Short Ratio
Av. Daily Volume 2,207,627

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 safety and factor expression data due 2019.
SB-525 cDNA gene therapy
Hemophilia A
Phase 1/2 initial safety and efficacy data due 2019.
ST-400
beta-thalassemia
Phase 1/2 longer-term safety and biochemical data due in 2019.
SB-318
MPS Type 1
Phase 1/2 data due 2019.
SB-FIX
Hemophilia B
Data at 2019 WORLDSymposium - February 7, 2019 noted insufficient creation of key enzyme. Additional data due later in 2019.
SB-913 - CHAMPIONS
MPS Type 2
Phase 1/2 trial to be initiated 2019.
ST-920
Fabry disease

Latest News

  1. Edited Transcript of SGMO earnings conference call or presentation 28-Feb-19 10:00pm GMT
  2. What Type Of Shareholder Owns Sangamo Therapeutics, Inc.’s (NASDAQ:SGMO)?
  3. Signal Says Sell This Biotech Stock
  4. Sangamo Therapeutics Appoints Jason Fontenot, Ph.D., As Senior Vice President, Cell Therapy
  5. Sangamo Therapeutics Announces Publication Of Data Demonstrating New Zinc Finger Nuclease Architectures Enabling High-Precision Genome Editing
  6. 5 Top Gene-Editing Stocks for 2019
  7. Sangamo Therapeutics Announces Participation At Upcoming Investor Conferences
  8. Why Sangamo Therapeutics Lost 22.9% of Its Value in February
  9. Sangamo Therapeutics Reports Fourth Quarter And Full Year 2018 Financial Results
  10. Sangamo Therapeutics Announces Fourth Quarter and Full Year 2018 Conference Call and Webcast
  11. Analysts Estimate Sangamo Therapeutics (SGMO) to Report a Decline in Earnings: What to Look Out for
  12. 2 Frustrating Flops, Plus Welcome to the Wrinkle Wars
  13. Investor Expectations to Drive Momentum within Sangamo Therapeutics, AVEO Pharmaceuticals, Everbridge, Huntington Ingalls Industries, Woodward, and SAP SE — Discovering Underlying Factors of Influence
  14. Sangamo Announces FDA Acceptance of IND Application for ST-920 Gene Therapy Candidate for Fabry Disease
  15. What's in Store for Sangamo (SGMO) This Earnings Season?
  16. Is Moderna a Buy?
  17. Biotech Stocks Rising
  18. Should Sangamo's Failure Make CRISPR Investors Nervous?
  19. Is Sangamo's Gene-Editing Approach a Bust?
  20. The Daily Biotech Pulse: Big Miss For Seattle Genetics; Hematology Conference Presentations; Gossamer Bio, Harpoon IPOs